P110δ Press Release

×

Status message

SESSION['ACCESSGRANTED'] value is
Post date Title Picture
Thu, 11/04/2021 - 19:08 CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021
CASI Pharmaceuticals's picture
CASI Pharmaceuticals
Thu, 10/07/2021 - 09:37 Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Patients With Breast Cancer
American Association for Cancer Research's picture
American Associ...
Fri, 09/17/2021 - 02:26 Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis's picture
Novartis
Wed, 04/28/2021 - 01:03 Cancer-linked mutation accelerates growth of abnormal stroke-causing brain blood vessels
NIH's picture
NIH
Tue, 03/31/2020 - 03:47 MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma
MEI Pharma's picture
MEI Pharma
Sun, 01/05/2020 - 20:29 Aspirin appears to curb colorectal cancer recurrence and tumor growth, study finds
City of Hope National Medical Center's picture
City of Hope Na...
Tue, 12/10/2019 - 04:53 Caris Life Sciences to Present Data Evaluating PI3K Pathway Alterations at the 2019 San Antonio Breast Cancer Symposium (SABCS)
Caris Life Sciences's picture
Caris Life Sciences
Mon, 10/21/2019 - 05:05 ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting
ArQule's picture
ArQule
Tue, 10/08/2019 - 08:47 ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
ArQule's picture
ArQule
Thu, 10/03/2019 - 21:57 MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies
MEI Pharma's picture
MEI Pharma
Wed, 10/02/2019 - 16:42 ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
ArQule's picture
ArQule
Tue, 06/11/2019 - 06:48 Stand Up To Cancer Hails FDA Approval of ALPELISIB + FULVESTRANT Combination For Patients With A PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer
Stand Up to Cancer's picture
Stand Up to Cancer
Mon, 06/10/2019 - 07:42 ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
ArQule's picture
ArQule
Tue, 05/28/2019 - 11:26 NeoGenomics and QIAGEN Collaborate to Offer Companion Diagnostic Test for HR+/HER2 - Advanced Breast Cancer Patients to Detect a PIK3CA Mutation
NeoGenomics's picture
NeoGenomics
Fri, 05/24/2019 - 14:31 Cancer research drives breast cancer treatment forward
Novartis's picture
Novartis
Fri, 05/24/2019 - 13:36 FDA approves first PI3K inhibitor for breast cancer
FDA's picture
FDA
Fri, 05/24/2019 - 03:58 FDA approves Novartis Piqray - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Novartis's picture
Novartis
Mon, 02/25/2019 - 09:24 ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome
ArQule's picture
ArQule
Thu, 12/06/2018 - 08:56 Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
Novartis's picture
Novartis
Wed, 12/05/2018 - 21:58 Liquid Biopsies in SOLAR-1 Trial Predict Benefit of Alpelisib in PIK3CA-Mutant Breast Cancer
American Association for Cancer Research's picture
American Associ...
Sat, 10/20/2018 - 17:56 Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
Novartis's picture
Novartis
Fri, 10/19/2018 - 06:30 ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092)
ArQule's picture
ArQule
Tue, 10/16/2018 - 06:12 Catalent And Verastem Oncology Partner On Newly Launched, FDA Approved COPIKTRA (duvelisib) Capsules
Catalent's picture
Catalent
Thu, 09/27/2018 - 07:05 US Bioservices selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules
AmerisourceBergen's picture
AmerisourceBergen
Fri, 06/15/2018 - 10:40 MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Synnex's picture
Synnex